Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
0.0002 USD 0.00(0%)
Last update at 2026-11-17T20:10:00Z
VOLUME
25000
Market Cap
0.76M

Momentum Score

…

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, and over"the"counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti"inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Nutra Pharma Corp (NPHC) is a micro-cap company quoted on the OTC Pink that states it is involved in development and commercialization of pharmaceutical and nutraceutical products; public disclosures are limited. Long-term growth may depend on successful product development, regulatory approvals and commercialization, and the company may appeal to investors seeking speculative exposure to early-stage healthcare ventures.
Principal risks include limited and irregular public reporting, low liquidity, an unproven product pipeline and significant execution and regulatory uncertainty that could lead to dilution or loss of investment.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.25M
Revenue Per Share
-
Gross Profit TTM
0.07M
Debt / Equity
-0.44
ROE
-
Net Debt
5.18M
ROCE
9.72%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax -0.77M -3.88M -6.59M -3.88M -4.03M
Net income -0.77M -3.88M -6.59M -3.88M -4.03M
Selling general administrative 1.93M 1.20M 1.20M 1.39M 1.48M
Gross profit 0.01M 0.01M 0.03M 0.01M 0.09M
Reconciled depreciation 0.06M 0.07M 0.08M 0.01M 0.01M
Ebit -1.09M -3.69M -1.23M 0.27M -1.38M
Ebitda -2.11M -3.69M -6.25M -3.29M -1.38M
Depreciation and amortization -1.03M 0.01M - - 0.01M
Non operating income net other - -5.10M - 2.15M -
Operating income -1.09M -1.88M -1.23M -1.88M -1.38M
Other operating expenses 1.14M 1.50M - - 1.50M
Interest expense 0.34M 0.59M 0.26M 0.59M 0.36M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.50M -0.34M -0.26M -0.59M -0.36M
Non recurring - 0.06M - - -
Income tax expense -0.76M -1.42M - - -2.29M
Total revenue 0.05M 0.13M 0.10M -1.88M 0.12M
Total operating expenses 1.10M 1.39M 1.33M -1.39M 1.48M
Cost of revenue 0.04M 0.12M 0.07M 2.01M 0.03M
Total other income expense net 0.32M -1.92M -5.10M -1.42M -2.29M
Net income from continuing ops -13.10M -6.59M -6.59M -3.88M -4.03M
Net income applicable to common shares -13.10M -6.59M -6.59M -3.88M -4.03M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - 0.30M 0.14M 0.34M 0.14M
Other current assets - 0.15M 0.06M 0.01M 0.06M
Total liab - 11.80M 6.08M 12.04M 6.08M
Total stockholder equity - -11.49M -5.94M -11.70M -5.94M
Other current liab - 5.96M 0.00M 0.84M 1.19M
Common stock - 6.96M 4.05M 5.88M 4.05M
Capital stock - 7.34M 6.96M 5.88M 4.05M
Retained earnings - -68.63M -61.27M -67.86M -61.27M
Other assets - 0.11M 0.09M 0.07M 0.02M
Cash - -0.14M -0.22M 0.00M 0.00M
Total current liabilities - 11.48M 6.03M 10.99M 6.03M
Current deferred revenue - 0.20M 2.02M - -
Net debt - 5.18M 3.58M 8.26M 3.58M
Short term debt - 4.73M 3.53M - 3.34M
Short long term debt - 7.60M 4.64M 7.35M 3.53M
Short long term debt total - 5.04M 3.58M - -
Other stockholder equity - 50.18M 51.29M - -
Property plant equipment - 0.14M 0.06M 0.21M 0.01M
Total current assets - 0.06M 0.12M 0.06M 0.12M
Net tangible assets - -20.89M -11.70M -11.70M -5.94M
Net receivables - 0.04M 0.02M 0.03M 0.02M
Long term debt - 0.52M 0.91M 0.91M 0.05M
Inventory - 0.01M 0.04M 0.01M 0.04M
Accounts payable - 0.60M 0.48M 0.58M 1.49M
Common stock total equity - - 5.88M - 4.05M
Preferred stock total equity - - 0.00M - 0.00M
Retained earnings total equity - - -67.86M - -61.27M
Non currrent assets other - 0.09M 0.02M 0.05M 0.02M
Non current assets total - 0.25M 0.03M 0.28M 0.03M
Capital lease obligations - 0.08M 0.14M 0.22M -
Long term debt total - - 0.91M - 0.05M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments -0.29M -0.01M - 0.00M -0.01M
Change to liabilities 0.07M 0.52M 0.11M 0.48M 0.13M
Total cashflows from investing activities -0.29M -0.01M -0.01M -0.01M -0.01M
Net borrowings 2.13M 0.74M 0.57M 0.11M 1.14M
Total cash from financing activities 0.88M 1.00M 0.74M 1.00M 1.12M
Change to operating activities 0.05M 0.32M 0.34M 0.41M 0.24M
Net income -0.77M -3.88M -6.59M -3.88M -4.03M
Change in cash 0.09M 1.00M 0.09M 0.09M 1.12M
Begin period cash flow 0.00M 0.00M 0.00M 1.15M 0.03M
End period cash flow 0.09M 0.00M 0.00M 0.00M 1.15M
Total cash from operating activities -0.88M -1.00M -0.74M -1.00M -1.14M
Depreciation 0.07M 0.01M 0.08M 0.38M 0.01M
Other cashflows from investing activities -0.25M -0.25M -0.25M -0.25M -
Change to inventory -0.02M -0.02M -0.03M -0.02M 0.01M
Change to account receivables -0.00M -0.00M -0.02M -0.00M 0.02M
Other cashflows from financing activities 1.05M 1.21M 0.17M 0.17M 1.62M
Change to netincome 10.89M 0.06M 5.26M 1.86M 2.37M
Capital expenditures 0.01M 0.01M 0.01M 0.01M 0.01M
Change receivables - -0.02M - -0.00M -
Cash flows other operating - 5.21M - 0.17M -
Change in working capital 0.30M 0.45M 0.41M 0.45M 0.40M
Stock based compensation 0.01M 0.07M 0.07M - 0.07M
Other non cash items 1.15M 2.71M 0.14M 0.61M 2.40M
Free cash flow -0.88M -1.00M -0.74M -1.00M -1.15M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NPHC
Nutra Pharma Corp
-
-%
0.00 - - 3.07 - 35.54 1.11
MKKGY
Merck KGaA ADR
0.40
1.22%
33.13 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
169.65 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
-
-%
21.64 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.15 - 10.66 0.01 1.16 2.94 23.11

Profile*

Nutra Pharma Corp

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, and over"the"counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti"inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

1537 NW 65th Avenue, Plantation, FL, United States, 33313

954 509 0911

4

Name Title Year Born
Mr. Erik J. Deitsch Chairman, CEO, Pres & CFO 1968
Dr. Dale VanderPutten MBA, Ph.D. Chief Scientific Officer 1959
Mr. Neil Roth Pres of Designer Diagnostics, Inc NA
Ms. Nina Goldstein Sec. 1960
Dr. Dale Vander Putten MBA, Ph.D. Chief Scientific Officer 1959
Dr. Michael D. Flax D.D.S., M.S., P.A. CEO, CFO & Chairman 1956
Joe Lucas Vice President of Operations NA
Ms. Nina Goldstein Secretary 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…